Ets-1 is a negative regulator of Th17 differentiation

por Moisan, Jacques, Grenningloh, Roland, Bettelli, Estelle, Oukka, Mohamed, Ho, I-Cheng
Publicado 2007

Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with...

por Naing, Aung, Eder, Joseph P, Piha-Paul, Sarina A, Gimmi, Claude, Hussey, Elizabeth, Zhang, Sen, Hildebrand, Vera, Hosagrahara, Vinayak, Habermehl, Christina, Moisan, Jacques, Papadopoulos, Kyriakos P
Publicado 2020

Novel synthetic RORγ agonist compounds as a potential anti-tumor therapeutic approach

por Hu, Xiao, Liu, Xikui, Morgan, Rodney, Moisan, Jacques, Hao, Ling-Yang, Wang, Yahong, Sanchez, Brian, Lesch, Charles, Bousley, Dick, Taylor, Clark, Aicher, Thomas, Toogood, Peter, Zou, Weiping, Glick, Gary, Carter, Laura
Publicado 2014

RORgamma agonists enhance survival and memory of type 17 T cells and improve anti-tumor activity

por Hu, Xiao, Moisan, Jacques, Majchrzak, Kinga, Lesch, Chuck, Wang, Yahong, Sanchez, Brian, Liu, Xikui, Morgan, Rodney, Mertz, David, Bousley, Dick, van Huis, Chad, Skalitzky, Don, Taylor, Clarke, Aicher, Thomas, Toogood, Peter, Zou, Weiping, Glick, Gary, Paulos, Chrystal, Carter, Laura
Publicado 2015

Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity

por Hu, Xiao, Liu, Xikui, Moisan, Jacques, Wang, Yahong, Lesch, Charles A., Spooner, Chauncey, Morgan, Rodney W., Zawidzka, Elizabeth M., Mertz, David, Bousley, Dick, Majchrzak, Kinga, Kryczek, Ilona, Taylor, Clarke, Van Huis, Chad, Skalitzky, Don, Hurd, Alexander, Aicher, Thomas D., Toogood, Peter L., Glick, Gary D., Paulos, Chrystal M., Zou, Weiping, Carter, Laura L.
Publicado 2016